Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 in BRAF or NRAS mutant melanoma
NCT01320085Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of binimetinib in cutaneous melanoma (CM), sponsored by Pfizer. Started Mar 2011; status: completed.
02
Drugs
binimetinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT01320085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01320085.